Table I.

Proportion of runs when the correct optimal dose was selected (CS); proportion of runs when the estimated optimal dose was shown to have efficacy no worse than active control and tolerability no worse than placebo (JOINT POWER); power to compare efficacy at the estimated optimal dose with active control (POWER RESPONSE CONTROL); power to compare adverse event rate at the estimated optimal dose with placebo (POWER AE PLACEBO); power to compare efficacy at the estimated optimal dose with placebo (POWER RESPONSE PLACEBO); and 25%, median, and 75% of the number of trials at the estimated optimal dose (SAMPLE SIZE QUANTILES). The two estimators of the optimal dose are presented: isotonic estimator (Adaptive 1) and best set of 2 doses estimator (Adaptive 2).

	CS	Joint Power	Power Response Control	Power AE Placebo	Power Response Placebo	Sample Size Quantiles (25%, median, 75%)
Scenario 1
Adaptive 1	0.74	0.86	0.90	0.95	0.97	68	81	89
Adaptive 2	0.72	0.86	0.89	0.97	0.96	70	81	89
Equal	0.70	0.70	0.82	0.86	0.99	40	40	40
Scenario 2
Adaptive 1	0.69	0.87	0.93	0.93	0.99	53	63	72
Adaptive 2	0.75	0.90	0.94	0.96	0.99	58	65	84
Equal	0.63	0.73	0.87	0.85	0.99	40	40	40
Scenario 3
Adaptive 1	0.77	0.80	0.96	0.82	0.025	69	84	94
Adaptive 2	0.78	0.87	0.99	0.88	0.025	77	85	95
Equal	0.80	0.58	0.81	0.74	0.025	40	40	40
Scenario 4
Adaptive 1	0.83	0.78	0.94	0.81	0.24	62	82	93
Adaptive 2	0.89	0.85	0.97	0.88	0.25	73	84	95
Equal	0.82	0.56	0.82	0.72	0.18	40	40	40
Scenario 5
Adaptive 1	0.73	0.65	0.92	0.71	0.24	44	76	92
Adaptive 2	0.72	0.68	0.97	0.70	0.26	65	81	93
Equal	0.72	0.53	0.87	0.65	0.24	40	40	40
Scenario 6
Adaptive 1	0.59	0.72	0.94	0.75	0.74	48	69	82
Adaptive 2	0.69	0.80	0.97	0.82	0.76	60	74	83
Equal	0.52	0.62	0.91	0.69	0.61	40	40	40